The reduction in price target may cause some investors to adjust their expectations for Humana's stock performance, potentially leading to short-term price volatility. However, the maintenance of a Buy rating suggests that Goldman Sachs still sees long-term value in the company, which could mitigate any negative reaction to the lower price target.